Exploratory Next Generation Sequencing to Identify Causative Variants for Bevacizumab-Induced Hypertension From Breast Cancer Study E5103 Germline DNA Samples
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 354
- 试验地点
- 1
- 主要终点
- Identification of rare coding variants of large effect that predict the risk of bevacizumab-induced hypertension
研究概览
简要总结
This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with hypertension receiving bevacizumab for breast cancer. Studying samples of germline DNA in the laboratory from patients with hypertension receiving bevacizumab for breast cancer may help doctors learn about changes that occur in DNA and identify biomarkers related to hypertension.
详细描述
PRIMARY OBJECTIVES:
I. To identify, using next generation sequencing, rare variants of large effect size that impact the risk of hypertension in patients from the clinical trial Eastern Cooperative Oncology Group (ECOG)-5103 (E5103).
OUTLINE:
Previously collected germline DNA samples are analyzed via whole exome sequencing.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Cross Sectional
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •European American patients with deoxyribonucleic acid (DNA) available and designated case or control
- •Patients who developed grade 3-4 bevacizumab-induced hypertension during their treatment with bevacizumab
- •Patients who did not develop hypertension following a full course of treatment with bevacizumab
排除标准
- 未提供
结局指标
主要结局
Identification of rare coding variants of large effect that predict the risk of bevacizumab-induced hypertension
时间窗: Baseline
Burden analysis will be used.
次要结局
未报告次要终点